Dr. Hsu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
525 East 68th Street
Box 251
New York, NY 10065Phone+1 212-746-2212
Education & Training
University of California (San Francisco)Fellowship, Blood Banking/Transfusion Medicine, 2013 - 2014
Washington University/B-JH/SLCH ConsortiumResidency, Pathology-Anatomic and Clinical, 2010 - 2013
McGovern Medical School at UTHealthClass of 2010
Certifications & Licensure
FL State Medical License 2024 - 2027
NY State Medical License 2014 - 2026
PA State Medical License 2021 - 2024
CA State Medical License 2013 - 2023- American Board of Pathology Pathology - Clinical
- American Board of Pathology Blood Banking/Transfusion Medicine
Publications & Presentations
PubMed
- 119 citationsMicromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity.Spencer Park, Enda Shevlin, Yogindra Vedvyas, Marjan Zaman, Susan Park
Scientific Reports. 2017-10-30 - 946 citationsCXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenanceAdam M. Greenbaum, Yen-Michael S. Hsu, Ryan B. Day, Laura G. Schuettpelz, Matthew J. Christopher
Nature. 2013-03-14 - 351 citationsThe adaptor protein CARD9 is required for innate immune responses to intracellular pathogensYen-Michael S. Hsu, Yongliang Zhang, Yun You, Donghai Wang, Hongxiu Li
Nature Immunology. 2007-02-01
Abstracts/Posters
- Thirty-Day Transfusion and G-CSF Requirement after CD19 CAR T InfusionYen-Michael S. Hsu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Fli-1 Transcriptionally Integrates Microenvironmental Cues Sensing By Self-Renewing Hematopoietic Stem and Progenitor CellsYen-Michael S. Hsu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
UPMC and Pitt Develop New Cancer Immunotherapy with Avalon GloboCareAugust 4th, 2021- UPMC, Avalon GloboCare Ink Partnership to Advance CAR T-cell TreatmentsAugust 2nd, 2021
Avalon GloboCare Corp. (NASDAQ: AVCO) Prepares Commercialization Launch of Its ACTEX Platform as Global Regenerative Therapeutics Outlook Looks RobustJune 27th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
